Literature DB >> 27390988

When is the right time for Fontan conversion? The role of cardiopulmonary exercise test.

Alexander C Egbe1, Heidi M Connolly2, Joseph A Dearani3, Crystal R Bonnichsen4, Talha Niaz5, Thomas G Allison6, Jonathan N Johnson7, Joseph T Poterucha8, Sameh M Said9, Naser M Ammash10.   

Abstract

BACKGROUND: To determine if Fontan conversion (FC) resulted in improvement in exercise capacity (EC), and to determine the role of cardiopulmonary exercise test (CPET) in risk stratification of patients undergoing FC.
METHODS: A retrospective review of patients who underwent CPET prior to FC at Mayo Clinic from 1994 to 2014. The patients who also underwent post-operative CPET were selected for the analysis of improvement in EC defined as 10% increase in baseline peak oxygen consumption (VO2).
RESULTS: 75 patients CPET prior to FC; mean age 24±6years; 44 males (59%); and 51 (68%) were in NYHA III/IV prior to FC. Pre-operative peak VO2 was 15.5±3.4ml/kg/min. A comparison of pre- and post-FC CPET data was performed using 42 patients (56%) that underwent CPET after FC. Improvement in EC occurred in 18 of 42 patients (43%). Baseline peak VO2 >14ml/kg/min was associated with improved EC (hazard ratio [HR] 1.85; P=.02). Improvement in New York Heart Association (NYHA) class occurred in 12 (67%) patients with improved EC vs 2 (8%) without improved EC. Improvement in NYHA class was more likely to occur in patients with improved EC compared to those without improvement EC (odds ratio 4.11, P=.01). There were 10 (13%) perioperative deaths, and baseline peak VO2 ≤14ml/kg/min was predictive of perioperative mortality (HR 3.74; P<.001).
CONCLUSIONS: Baseline peak VO2 was predictive of perioperative survival, and improvement in EC. Performance on CPET in failing Fontan patients might be a useful clinical parameter in determining appropriate timing of FC.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cardiopulmonary exercise test; Exercise capacity; Fontan conversion

Mesh:

Year:  2016        PMID: 27390988     DOI: 10.1016/j.ijcard.2016.06.209

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

1.  Longitudinal Outcomes of Epicardial and Endocardial Pacemaker Leads in the Adult Fontan Patient.

Authors:  Geoffrey D Huntley; Abhishek J Deshmukh; Carole A Warnes; Suraj Kapa; Alexander C Egbe
Journal:  Pediatr Cardiol       Date:  2018-06-14       Impact factor: 1.655

2.  Vortex Flow in the Right Atrium Surrogates Supraventricular Arrhythmia and Thrombus After Atriopulmonary Connection-Type Fontan Operation: Vortex Flow Analysis Using Conventional Cine Magnetic Resonance Imaging.

Authors:  Yumi Shiina; Kei Inai; Tatsunori Takahashi; Yamato Shimomiya; Umiko Ishizaki; Kenji Fukushima; Michinobu Nagao
Journal:  Pediatr Cardiol       Date:  2017-11-02       Impact factor: 1.655

3.  Outcomes of the Conversion of the Fontan-Kreutzer Operation to a Total Cavopulmonary Connection for the Failing Univentricular Circulation.

Authors:  Gabriel Carmona Fernandes; Guilherme Viotto Rodrigues da Silva; Luiz Fernando Caneo; Carla Tanamati; Aida Luiza Ribeiro Turquetto; Marcelo Biscegli Jatene
Journal:  Arq Bras Cardiol       Date:  2019-02       Impact factor: 2.000

4.  Hemodynamics of Fontan Failure: The Role of Pulmonary Vascular Disease.

Authors:  Alexander C Egbe; Heidi M Connolly; William R Miranda; Naser M Ammash; Donald J Hagler; Gruschen R Veldtman; Barry A Borlaug
Journal:  Circ Heart Fail       Date:  2017-12       Impact factor: 8.790

5.  Echocardiographic predictors of severe right ventricular diastolic dysfunction in tetralogy of Fallot: Relations to patient outcomes.

Authors:  Alexander C Egbe; Patricia A Pellikka; William R Miranda; Crystal Bonnichsen; Yogesh N V Reddy; Barry A Borlaug; Heidi M Connolly
Journal:  Int J Cardiol       Date:  2020-02-27       Impact factor: 4.164

6.  Venous congestion and pulmonary vascular function in Fontan circulation: Implications for prognosis and treatment.

Authors:  Alexander C Egbe; Yogesh N V Reddy; Arooj R Khan; Mohamad Al-Otaibi; Emmanuel Akintoye; Masaru Obokata; Barry A Borlaug
Journal:  Int J Cardiol       Date:  2018-11-15       Impact factor: 4.164

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.